Registered title, quoted from ClinicalTrials.gov
Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 7 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 7
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteFifth Affiliated Hospital of Guangzhou Medical University广州医科大学附属第五医院GuangzhouHospital page
- Study siteFirst Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院GuangzhouHospital page
- Study siteFirst People's Hospital of Foshan佛山市第一人民医院FoshanHospital page
- Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
- Study siteRenmin Hospital of Wuhan University武汉大学人民医院WuhanHospital page
- Study siteShanghai Chest Hospital上海市胸科医院ShanghaiHospital page
- Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06518655, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 80 years; sex: all
Registered eligibility fields
Patients require pulmonary nodule resection to define the type of nodule pathology;
Inclusion criterion 3
Patients are unable to determine the pathological diagnosis of pulmonary nodules after surgical resection or biopsy;
Exclusion criterion 2
Pulmonary nodules were detected through low-dose spiral CT, chest CT conventional scan, or high-resolution thin-layer CT examination, with a maximum diameter of 5-30 mm, including solid nodules and ground glass nodules;
Inclusion criterion 2
Confirmed HIV patients;
Exclusion criterion 9
Pregnant or lactating women;
Exclusion criterion 10
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06518655, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 18-80 years old;
- Pulmonary nodules were detected through low-dose spiral CT, chest CT conventional scan, or high-resolution thin-layer CT examination, with a maximum diameter of 5-30 mm, including solid nodules and ground glass nodules;
- Patients require pulmonary nodule resection to define the type of nodule pathology;
- The Patients have not yet used any drugs for tumor treatment;
- Patients and/or family members are able to understand the research protocol and are willing to participate in this study, providing written informed consent.
Exclusion Criteria:
- The maximum diameter of pulmonary nodules is greater than 30 mm;
- Patients are unable to determine the pathological diagnosis of pulmonary nodules after surgical resection or biopsy;
- Patients with recurrent lung cancer;
- Patients who have undergone lung transplantation or lobectomy;
- Individuals who currently or have a history of malignant tumors;
- Patients in the acute phase of inflammation or in need of intensive care in the above selected disease groups;
- Individuals with severe liver and kidney dysfunction;
- Mental illness patients (such as severe dementia, schizophrenia, severe depression, manic depressive psychosis, etc.);
- Confirmed HIV patients;
- Pregnant or lactating women;
- Patients or family members are unable to understand the conditions and objectives of this study.
- The patient is unwilling or unable to personally sign the informed consent form.
Quoted from ClinicalTrials.gov, NCT06518655, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06518655, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.